查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405878

抗生素市场规模、份额、趋势分析报告：按作用机制、药物类别、类型、细分市场预测，2024-2030

Antibiotics Market Size, Share & Trends Analysis Report By Action Mechanism (Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors), By Drug Class (Penicillin, Cephalosporin), By Type (Branded, Generic), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 145 Pages | 商品交期: 2-10个工作天内

价格

抗生素市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球抗生素市场规模将达到680.3亿美元，2024年至2030年复合年增长率为4.2%。

高需求、对抗生素抗药性计划的日益关注、避免滥用抗生素的努力以及学名药的容易获得是促进市场成长的因素。抗生素的购买过程主要受到医师的影响。多种学名药可供选择，方便买家转换。对于医疗保健企业来说，价格折扣在选择过程中扮演着重要角色。这进一步降低了市场相关人员的报酬率。然而，对于品牌或专利产品，买家没有这种特权。

此外，监管机构也发布了限制奎诺酮使用的指南。因此，预计预测期内买家的议价能力较低。根据《世界抗生素状况》报告，2021 年印度抗生素整体使用量将激增 30%。此外，根据 CDC 的《美国抗生素使用报告》（2021 年更新），美国零售药局配发了约 2,500 万张处方笺。其中，阿奇霉素是2021年处方的主要剂型。因此，抗生素消费模式的增加可能会在预测期内推动市场成长。新产品的核准和推出预计将支持市场成长。

例如，2020年6月，美国FDA宣布核准西司他组合药物-Imipenem和瑞巴坦的复方药物Recarbrio，用于治疗人工呼吸器相关细菌性肺炎和院内细菌性肺炎。本产品于2019年7月首次核准用于治疗腹内及尿道感染感染疾病（UTI）。 《立即制定抗生素激励法案》、全球抗菌素抗药性研究 (GRAM) 计画和全球抗生素研究与开发伙伴关係 (GARDP) 等政府倡议预计将在未来几年推动市场成长。此外，这些组织有望推动尖端先进药物的开发过程，并促进抗生素药物的核准过程。

抗生素市场报告亮点

  • 由于新开发的抗生素缺乏商业性成功，政府和非政府组织实施了某些策略来奖励抗菌药物研发活动。
  • 例如，政府与 BARDA 的合作支持各公司加速感染疾病新治疗方法的研发工作。 BARDA 与阿斯特捷利康 (AstraZeneca) 和葛兰素史克 (GSK plc) 等多家製药公司合作。
  • 由于其针对革兰氏阳性和革兰氏阴性细菌的频谱活性，细胞壁合成抑制剂部分在 2023 年占最大份额。
  • 由于产品推出和倡议计划的激增，RNA 合成抑制剂领域预计将在 2024 年至 2030 年实现最快的复合年增长率。
  • 由于非专利药配方价格实惠以及政府采用学名药的倡议，非专利药细分市场在 2023 年占据最大份额。
  • 青霉素类药物细分市场将在 2023 年推动市场发展。然而，预计 2024 年至 2030 年头孢菌素类药物的复合年增长率最快。
  • 由于领先公司的投资增加和非专利药的高采用率，预计亚太地区在预测期内将呈现最快的复合年增长率。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章抗生素市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 抗生素市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章抗生素市场：药物类别的估计和趋势分析

  • 2023年及2030年药品类别市场占有率
  • 细分仪表板
  • 按药物类别分類的全球抗生素市场展望
  • 2018年至2030年市场规模、预测与趋势分析如下
    • 头孢菌素
    • 青霉素
    • 奎诺酮
    • 大环内酯系列
    • 碳青霉烯类
    • Aminoglycosides
    • 磺胺类药物
    • 7-ACA
    • 其他的

第五章抗生素市场：类型估计和趋势分析

  • 类型市场占有率，2023 年和 2030 年
  • 细分仪表板
  • 按类型分類的全球抗生素市场展望
  • 2018年至2030年市场规模、预测与趋势分析如下
    • 品牌抗生素
    • 非专利抗生素

第六章抗生素市场：作用机制估计与趋势分析

  • 2023年及2030年作用机制市场占有率
  • 细分仪表板
  • 按作用机转分類的全球抗生素市场展望
  • 2018年至2030年市场规模、预测与趋势分析如下
    • 细胞壁合成抑制剂
    • 蛋白质合成抑制剂
    • DNA合成抑制剂
    • RNA合成抑制剂
    • 霉菌酸抑制剂
    • 其他的

第七章抗生素市场：区域估计和趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模及预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争分类
  • 供应商形势
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023 年主要企业股票分析
    • AbbVie, Inc.
    • Pfizer Inc.
    • Novartis AG
    • Merck &Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Lupin Pharmaceuticals, Inc.
    • Viatris, Inc.
    • Melinta Therapeutics LLC
    • Cipla, Inc.
    • Shionogi &Co., Ltd.
    • KYORIN Pharmaceutical Co., Ltd.
    • GSK plc
    • Nabriva Therapeutics PLC
Product Code: GVR-1-68038-149-8

Antibiotics Market Growth & Trends:

The global antibiotics market size is expected to reach USD 68.03 billion by 2030, registering a CAGR of 4.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. High demand, increasing focus on antibiotic resistance programs, initiatives undertaken to avoid the misuse of antibiotics, and easy availability of generic drugs are responsible for market growth. The purchasing process of antibiotics is primarily influenced by physicians. The availability of multiple generic products provides buyers with easy switching options. In the case of institutional businesses, price discounts play an important role in the selection procedure. This can further reduce the profit margins of market players. However, buyers do not have these privileges in branded or patented products.

Furthermore, regulatory authorities have issued the guidelines for limited use of fluoroquinolones. Hence, the bargaining power of buyers is anticipated to be low over the forecast period. According to the State of World's Antibiotics report, in 2021, the overall antimicrobial drug usage in India has increased sharply by 30%. Moreover, according to the CDC's Antibiotics Usage in United States report, 2021 update, around 25 million prescriptions were dispensed from U.S. retail pharmacies. Among them, azithromycin was the leading formulation prescribed in 2021. Thus, the rising consumption pattern of antibacterial drugs is likely to fuel the market growth during the projected period. New product approvals and launches are expected to support market growth.

For instance, in June 2020, the U.S. FDA announced the approval of Recarbrio, a combination of cilastatin-imipenem and relebactam, for the treatment of ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia. The product was first approved for intra-abdominal infections and Urinary Tract Infections (UTIs) in July 2019. In the upcoming years, market growth is projected to be driven by governmental measures, such as the Generating Antibiotics Incentives Now Act, Global Research on Antimicrobial Resistance (GRAM) Project, and the Global Antibiotic Research & Development Partnership (GARDP). Moreover, these organizations are expected to propel the process of developing cutting-edge advanced medications and smoothen the approval process of antibiotic drugs.

Antibiotics Market Report Highlights:

  • Owing to the dearth of commercial success of newly developed antibiotics, government & non-government bodies implemented certain strategies to incentivize antibacterial drug R&D activities
  • For instance, the government alliance with BARDA is supporting various companies to facilitate R&D activities in novel therapies for infectious diseases. BARDA has been associated with several pharmaceutical companies like AstraZeneca and GSK plc
  • The cell wall synthesis inhibitor segment held the largest share in 2023 owing to its wide spectrum of activity against gram-positive and gram-negative bacteria
  • The RNA synthesis inhibitors segment is anticipated to register the fastest CAGR from 2024 to 2030 due to a surge in product launches and R&D initiatives
  • The generic type segment held the largest share in 2023 due to the affordability of generic formulations and government initiatives to adopt generic drugs
  • The penicillin drug class segment led the market in 2023. However, the cephalosporin segment is anticipated to register the fastest CAGR from 2024 to 2030
  • Asia Pacific is expected to exhibit the fastest CAGR over the forecast period due to the rising investments by leading players and the high adoption of generic antibiotics in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Type
    • 1.2.3. Action Mechanism
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class
    • 2.2.2. Type
    • 2.2.3. Action Mechanism
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antibiotics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Development of advanced products
      • 3.2.1.2. Increasing prevalence of infectious diseases
      • 3.2.1.3. Growing collaborations for development of antibiotics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High number of patent expirations
      • 3.2.2.2. High R&D cost
  • 3.3. Antibiotics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Antibiotics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Antibiotics Market by Drug Class Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Cephalosporin
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Penicillin
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Fluoroquinolone
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Macrolides
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Carbapenems
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Aminoglycosides
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7. Sulfonamides
      • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.8. 7-ACA
      • 4.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.9. Others
      • 4.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antibiotics Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Antibiotics Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Branded Antibiotics
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Generic Antibiotics
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Antibiotics Market: Action Mechanism Estimates & Trend Analysis

  • 6.1. Action Mechanism Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Antibiotics Market by Action Mechanism Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Cell Wall Synthesis Inhibitors
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Protein Synthesis Inhibitors
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. DNA Synthesis Inhibitors
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. RNA Synthesis Inhibitors
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Mycolic Acid Inhibitors
      • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Antibiotics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. AbbVie, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Pfizer Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Novartis AG
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Merck & Co., Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Teva Pharmaceutical Industries Ltd.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Lupin Pharmaceuticals, Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Viatris, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Melinta Therapeutics LLC
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Cipla, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Shionogi & Co., Ltd.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. KYORIN Pharmaceutical Co., Ltd.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. GSK plc
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
    • 8.3.16. Nabriva Therapeutics PLC
      • 8.3.16.1. Company overview
      • 8.3.16.2. Financial performance
      • 8.3.16.3. Product benchmarking
      • 8.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Antibiotics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 6 U.S. Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S. Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 9 Canada Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Canada Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 12 Europe Antibiotics market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Europe Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 15 Europe Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 16 Germany Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Germany Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 18 Germany Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 19 UK Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 UK Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 21 UK Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 22 France Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 France Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 24 France Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 25 Italy Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 Italy Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 27 Italy Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 28 Spain Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Spain Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 30 Spain Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 31 Denmark Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Denmark Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 34 Sweden Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 Sweden Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 37 Norway Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Norway Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 39 Norway Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Antibiotics market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 44 China Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 China Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 46 China Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 47 Japan Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Japan Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 49 Japan Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 50 India Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 India Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 52 India Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 53 South Korea Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 South Korea Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 55 South Korea Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 56 Australia Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 57 Australia Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 58 Australia Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 59 Thailand Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 Thailand Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 62 Latin America Antibiotics market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 Latin America Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 65 Latin America Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 66 Brazil Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 67 Brazil Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 68 Brazil Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 69 Mexico Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 70 Mexico Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 71 Mexico Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 72 Argentina Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 73 Argentina Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 74 Argentina Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 75 MEA Antibiotics market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 77 MEA Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 78 MEA Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 79 South Africa Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 80 South Africa Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 81 South Africa Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 85 UAE Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 86 UAE Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 87 UAE Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Antibiotics market, by drug class, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Antibiotics market, by type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Antibiotics market, by action mechanism, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Antibiotics market: market outlook
  • Fig. 14 Antibiotics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Antibiotics market driver impact
  • Fig. 20 Antibiotics market restraint impact
  • Fig. 21 Antibiotics market strategic initiatives analysis
  • Fig. 22 Antibiotics market: Drug Class movement analysis
  • Fig. 23 Antibiotics market: Drug Class outlook and key takeaways
  • Fig. 24 Cephalosporin market estimates and forecast, 2018 - 2030
  • Fig. 25 Penicillin market estimates and forecast, 2018 - 2030
  • Fig. 26 Fluoroquinolone market estimates and forecast, 2018 - 2030
  • Fig. 27 Macrolides market estimates and forecast, 2018 - 2030
  • Fig. 28 Carbapenems market estimates and forecast, 2018 - 2030
  • Fig. 29 Aminoglycosides market estimates and forecast, 2018 - 2030
  • Fig. 30 Sulfonamides market estimates and forecast, 2018 - 2030
  • Fig. 31 7-ACA market estimates and forecast, 2018 - 2030
  • Fig. 32 Others market estimates and forecast, 2018 - 2030
  • Fig. 33 Antibiotics Market: Type movement Analysis
  • Fig. 34 Antibiotics market: Type outlook and key takeaways
  • Fig. 35 Branded Antibiotics market estimates and forecasts, 2018 - 2030
  • Fig. 36 Generic Antibiotics market estimates and forecasts,2018 - 2030
  • Fig. 37 Antibiotics market: Action Mechanism movement analysis
  • Fig. 38 Antibiotics market: Action Mechanism outlook and key takeaways
  • Fig. 39 Cell Wall Synthesis Inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 40 Protein Synthesis Inhibitors market estimates and forecasts,2018 - 2030
  • Fig. 41 DNA Synthesis Inhibitors market estimates and forecasts,2018 - 2030
  • Fig. 42 RNA Synthesis Inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 43 Mycolic Acid Inhibitors market estimates and forecasts,2018 - 2030
  • Fig. 44 Others market estimates and forecasts, 2018 - 2030
  • Fig. 45 Global Antibiotics market: Regional movement analysis
  • Fig. 46 Global Antibiotics market: Regional outlook and key takeaways
  • Fig. 47 Global Antibiotics market share and leading players
  • Fig. 48 North America market share and leading players
  • Fig. 49 Europe market share and leading players
  • Fig. 50 Asia Pacific market share and leading players
  • Fig. 51 Latin America market share and leading players
  • Fig. 52 Middle East & Africa market share and leading players
  • Fig. 53 North America: SWOT
  • Fig. 54 Europe SWOT
  • Fig. 55 Asia Pacific SWOT
  • Fig. 56 Latin America SWOT
  • Fig. 57 MEA SWOT
  • Fig. 58 North America, by country
  • Fig. 59 North America
  • Fig. 60 North America market estimates and forecasts, 2018 - 2030
  • Fig. 61 U.S.
  • Fig. 62 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 63 Canada
  • Fig. 64 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 65 Europe
  • Fig. 66 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 67 UK
  • Fig. 68 UK market estimates and forecasts, 2018 - 2030
  • Fig. 69 Germany
  • Fig. 70 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 71 France
  • Fig. 72 France market estimates and forecasts, 2018 - 2030
  • Fig. 73 Italy
  • Fig. 74 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 75 Spain
  • Fig. 76 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 77 Denmark
  • Fig. 78 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 79 Sweden
  • Fig. 80 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 81 Norway
  • Fig. 82 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 83 Asia Pacific
  • Fig. 84 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 85 China
  • Fig. 86 China market estimates and forecasts, 2018 - 2030
  • Fig. 87 Japan
  • Fig. 88 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 89 India
  • Fig. 90 India market estimates and forecasts, 2018 - 2030
  • Fig. 91 Thailand
  • Fig. 92 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 93 South Korea
  • Fig. 94 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 95 Australia
  • Fig. 96 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 97 Latin America
  • Fig. 98 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 99 Brazil
  • Fig. 100 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 101 Mexico
  • Fig. 102 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 103 Argentina
  • Fig. 104 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 105 Middle East and Africa
  • Fig. 106 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 107 South Africa
  • Fig. 108 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 109 Saudi Arabia
  • Fig. 110 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 111 UAE
  • Fig. 112 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 113 Kuwait
  • Fig. 114 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 115 Market share of key market players- Antibiotics market